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ABSTRACT
Introduction: Streptococcus pneumoniae is a major cause of morbidity and mortality. We
sought to describe the epidemiology of non-invasive and invasive pneumococcal disease in
a national Veterans Affairs population.
Methods: We conducted a retrospective study in older patients (aged ≥50 years) with
positive pneumococcal cultures from any site within the United States between 2002 and
2011. We described outpatient and inpatient pneumococcal disease incidence per 100,000
clinic visits/hospitalizations. Repeat cultures within a 30-day period were considered to
represent the same episode. To describe the epidemiology of serious pneumococcal
infections (bacteremia, meningitis, pneumonia), we assessed demographics, clinical
characteristics, and risk factors for S. pneumoniae. Pneumonia was defined as a positive
respiratory culture with a pneumonia diagnosis code. Bacteremia and meningitis were
identified from positive cultures. Generalized linear mixed models were used to quantify
changes over time.
Results: Over the study period, we identified 45,983 unique episodes of pneumococcal
disease (defined by positive cultures). Incidence decreased significantly by 3.5% per year in
outpatients and increased non-significantly by 0.2% per year in inpatients. In 2011, the
outpatient and inpatient incidence was 2.6 and 328.1 infections per 100,000 clinic
visits/hospitalizations, respectively. Among inpatients with serious infections, chronic disease
risk factors for pneumococcal disease increased significantly each year, including respiratory
disease (1.9% annually), diabetes (1.3%), and renal failure (1.0%). Overall, 30.2% of
inpatients with serious infections had a pneumococcal immunization in the previous 5 years.
Invasive disease (37.4% versus 34.9%, P = 0.004) and mortality (14.0% versus 12.7%,
P = 0.045) were higher in non-vaccinated patients compared to vaccinated patients.
Conclusions: In our national study of older adults, the baseline health status of those with
serious pneumococcal infections worsened over the study period. As the population ages
and the chronic disease epidemic grows, the burden of pneumococcal disease is likely to
increase thus highlighting the importance of pneumococcal vaccination.
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INTRODUCTION
Streptococcus pneumoniae (pneumococcus) is a major cause of morbidity and mortality in
the United States (US), causing over 500,000 cases of pneumonia, over 40,000 cases of
invasive pneumococcal disease, and 4,000 associated deaths annually [1, 2]. S.
pneumoniae is differentiated by one of at least 90 different polysaccharide capsules [3]. The
capsule acts as the major virulence factor protecting the pathogen from destruction by host
phagocytes [3]. S. pneumoniae is part of the normal bacterial flora of the upper respiratory
tract and is mainly found in the nasopharynx.
Pneumococcus causes a wide variety of invasive (such as bacteremia and
meningitis) and non-invasive infections (such as pneumonia, sinusitis, and otitis media) [4,
5]. A number of patient demographics and comorbidities, including age, diabetes mellitus,
chronic lung disease, chronic liver disease, chronic cardiovascular disease, chronic renal
failure, and immune deficiencies, increase one’s risk of developing pneumococcal disease
[6–10]. In patients with underlying medical conditions the incidence of pneumococcal
infections may be as high as 176 to 483 per 100,000 persons, while the incidence for
patients with immunocompromising conditions has been reported to be even higher from 342
to 2,031 per 100,000 persons [6, 11].
Since the introduction and widespread use of the pneumococcal conjugate vaccine in
children in 2000, the incidence of invasive pneumococcal disease in the US has decreased
[12–17]. Vaccinating children provides indirect protection or "herd immunity" to nonvaccinated adults, and has led to a nearly one-third decrease in the rate of invasive
pneumococcal disease among adults aged 50 and older [13, 17]. Subsequent changes in
the epidemiology of S. pneumoniae infections are not well-described, particularly among
high-risk patients. Therefore, we sought to describe changes in the epidemiology from 2002
to 2011 of pneumococcal disease nationally among adults aged 50 years and older in the
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Veterans Affairs (VA) Healthcare System, specifically disease incidence and risk factors for
S. pneumoniae among those with serious pneumococcal infections.

METHODS
The study design and methods were reviewed and approved by the Institutional Review
Board and Research and Development Committee of the Providence VA Medical Center.
This article does not contain any new studies with human or animal subjects performed by
any of the authors.
Data Sources
The Veterans Health Administration operates 151 medical centers and 827 communitybased outpatient clinics throughout the US [18]. Inpatient and outpatient care is captured
electronically in each VA healthcare facility through the electronic medical record system,
which has been in place since 1999 [19]. We identified S. pneumoniae using microbiology
data and merged data from multiple domains, including demographics, medical, and
immunization to capture patient care [20, 21]. International Classification of Diseases, 9th
Revision (ICD-9) diagnostic and procedure codes from inpatient and outpatient records were
utilized to identify patient comorbidities, risk factors, and infection history [22, 23].
Immunization administration records were used to determine vaccination rates.
Patient Population and Study Design
We conducted a descriptive, retrospective study of patients age 50 years and older with
microbiology cultures from any collection site positive for S. pneumoniae between January 1,
2002 and December 31, 2011. To assess incidence, both inpatient and outpatient cultures
were included. Repeat positive S. pneumoniae cultures from the same patient within a 30day period were considered to represent the same episode of infection [24]. Yearly incidence
rates were calculated as the number of pneumococcal infections per 100,000 clinic visits or
per 100,000 hospital admissions.
To describe the epidemiology of serious (bacteremia, meningitis, and pneumonia) S.
pneumoniae infections, we included positive respiratory, blood, or cerebrospinal fluid
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cultures collected during a hospital admission. Bacteremia and meningitis were identified
from positive cultures. Pneumonia was defined as a positive respiratory culture with a
corresponding ICD-9 code for pneumonia (482.40–482.42, 482.49, 482.89, 482.9, 484.8,
485–486, 510.0, 510.9, 513.0–513.1) [22, 23]. Invasive pneumococcal disease was
categorized as bacteremia, meningitis, and bacteremic pneumonia, and non-invasive
disease included pneumonia without bacteremia. Bacteremic pneumonia was defined by the
presence of both pneumococcal pneumonia and bacteremia.
Patient Characteristics
We evaluated demographic and clinical characteristics among inpatients infected with
serious S. pneumoniae infections [22, 23]. Diagnosed infections in the year prior to the
positive pneumococcal culture, such as pneumonia and bacteremia (attributed to any
organism), and Streptococcal infections (any infection type attributed to any Streptococcus
species), were assessed. Risk factors for S. pneumoniae were evaluated including heart
failure, chronic respiratory disease, diabetes mellitus, chronic liver disease, human
immunodeficiency virus (HIV), chronic renal disease, immunodeficiency syndromes, and
cancer. Pneumococcal vaccination was defined as any pneumococcal immunization
administration record in the previous 1, 5, and 10 years prior to the culture collection date.
As the conjugate vaccine was not recommended for use in adults until 2012, our vaccination
rates reflect vaccination with 23-valent pneumococcal polysaccharide vaccine only [25].
Inpatient mortality was defined as death from any cause during the pneumococcal-related
admission and 30-day mortality was defined as death from any cause within 30-days of the
culture collection date.
Statistical Analysis
Descriptive statistics were calculated, including number and percent for categorical
characteristics, mean and standard deviation for normally distributed continuous variables,
and median and interquartile range (IQR) for non-normal variables. To assess fluctuations in
incidence over time, modeled annualized change and percent change in incidence were
determined with generalized linear mixed models. Additionally, generalized linear mixed
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models quantified the modeled annualized percent change in S. pneumoniae risk factors
over the study period. Differences between vaccinated and non-vaccinated patients were
assessed using Chi-square or Fisher exact tests for categorical variables and the t-test or
Wilcoxon rank sum test for continuous variables as appropriate. A two-tailed P value of 0.05
or less was considered statistically significant. All analyses were performed using SAS
version 9.3 (SAS Institute Inc., Cary, NC, USA).

RESULTS
Over the 10-year study period, we identified 45,983 unique episodes of pneumococcal
disease (defined by positive cultures; 62.9% outpatient and 37.1% inpatient). Positive
cultures were obtained from the following sites: respiratory (43.0%), urine (23.2%), blood
(16.9%), skin (11.8%), and other (such as nares, bone, joint, and cerebrospinal fluid; 5.2%).
The median time to culture collection from admission for inpatients was 0 days (IQR 0-1
days).
From 2002 to 2011, pneumococcal disease incidence (as defined from positive
cultures) decreased from 5.8 to 2.9 infections per 100,000 clinic visits for outpatients and
increased from 262.3 to 328.1 infections per 100,000 hospital admissions for inpatients
(Table 1). Outpatient pneumococcal disease incidence decreased significantly by 3.5% per
year, while there was a non-significant 0.2% per year increase in incidence of inpatient
pneumococcal disease over the study period. Outpatient incidence decreased significantly
per year for patients aged 50 to 64 years and also for patients aged 65 years and older.
Inpatient incidence decreased by 0.6% per year for patients aged 50 to 64 years, and
increased by 0.7% per year for patients aged 65 years and older. Inpatient invasive disease
incidence decreased by 1.0% per year.
There were 14,511 unique episodes of serious (bacteremia, meningitis, and
pneumonia) S. pneumoniae infections over the study period (Table 2). Non-invasive
pneumonia was the most common infection (63.4%, n = 9,193), followed by bacteremia
(25.7%, n = 3,735), bacteremic pneumonia (10.5%, n = 1,529), bacteremia and meningitis
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(0.2%, n = 23), and meningitis alone (0.1%, n = 21). The overall mean age of this population
was 67.7 ± 10.6 years. The majority of patients were white males from facilities in the South
for all infection types. The most common treating specialty was general medicine (57.5%,
n=8,351), followed by intensive care (25.9%, n = 3,758).
Approximately 30% of patients in each infection group received the pneumococcal
vaccine (Table 2). History of multiple pneumococcal infections during the study period
ranged from 30% to 40% for all infection types. One-third of patients with both invasive and
non-invasive pneumococcal pneumonia had a pneumonia ICD-9 diagnosis in the year prior
to the positive pneumococcal culture. Overall, 11.9% of patients had an ICD-9 diagnosis for
a Streptococcal infection (from any Streptococcus species, including S. pneumoniae) in the
previous year. Among inpatients with serious infections, 40.2% had chronic respiratory
disease, 16.2% had diabetes, 16.2% had cancer, and 14.6% had heart failure.
Approximately 12% of patients used tobacco, and the highest percentage of tobacco use
was among those with non-invasive pneumonia (14.0%). Overall inpatient mortality and 30day mortality rates were 13.6% and 17.9%, respectively. The highest mortality was among
those with bacteremic pneumonia (inpatient mortality 29.1%; 30-day mortality 28.8%) and
the lowest was among those with non-invasive pneumonia (inpatient mortality 9.5%; 30-day
mortality 14.2%).
Prevalence of risk factors for S. pneumoniae among inpatients with serious
pneumococcal infections are presented for each year of the study period in Table 3. In 2011,
chronic respiratory disease (50.9%) and diabetes (22.6%) were the most common conditions
in our population, while immunodeficiency disorders (0.2%) and HIV (1.8%) were the least
common risk factors. The modeled annual percent change increased significantly for all risk
factors assessed, except HIV and immunity disorders where the increase was nonsignificant. Chronic respiratory disease, diabetes, and renal failure increased by 1.9%, 1.3%,
and 1.0% per year, respectively.
Table 4 compares demographics, comorbid conditions, and healthcare exposures
among patients vaccinated within 5 years of infection and those not vaccinated within 5
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years of infection. A number of patient characteristics varied significantly between the two
groups, including race, region of facility, and infection type. Patients with a history of multiple
pneumococcal infections during the study period and patients with other infection types in
the year prior were more likely to be vaccinated. Additionally, patients with several comorbid
conditions, including heart failure, diabetes, and chronic renal disease, were more likely to
be vaccinated. Invasive disease was more common in non-vaccinated patients (37.4%
versus 34.9%, P = 0.004), as was inpatient mortality (14.0% versus 12.6%, P = 0.04).
Similar significant differences were observed when comparing vaccination (n=5,274) versus
non-vaccination (n = 9,237) in the previous 10 years (data not presented).

DISCUSSION
We assessed the burden of invasive and non-invasive pneumococcal disease in a large
population of adults aged 50 years and older receiving care at outpatient and inpatient VA
facilities nationally. While outpatient incidence decreased, a small, non-significant increase
in pneumococcal infections was observed in the hospital setting over our 10-year study
period. The decrease in outpatient incidence in our population is likely associated with
routine

pneumococcal

conjugate

vaccination

in

children.

Previous

studies

have

demonstrated decreasing rates of invasive and non-invasive pneumococcal disease
including, otitis media and pneumonia, post-introduction of the pneumococcal conjugate
vaccine [13, 17, 26–28]. It is possible that non-vaccine serotypes were responsible for the
slight increase in pneumococcal disease we observed in our inpatient population; however
serotype data were not available. In a previous multi-center observational study the annual
rate of bacteremic pneumococcal disease due to vaccine serotypes declined by 29% per
year, however, the rate of disease due to non-vaccine serotypes increased by 13% per year,
resulting in an overall annual increase [29].
Our aging Veteran population may also explain the slight increase in inpatient
pneumococcal infections we observed. Incidence increased in patients aged 65 years and
older, while incidence decreased in younger patients. Elderly patients are at the highest risk
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for pneumococcal disease and disease incidence in these patients is up to 50 times greater
than that of adolescents [30]. As the general population ages, the burden of pneumococcal
disease is expected to dramatically increase [31]. This increase may be exacerbated in the
Veteran population, which is older than the general population and is aging at a
disproportionate rate compared to the general population [32–34].
Non-invasive pneumococcal pneumonia is generally not included in S. pneumoniae
surveillance; however, S. pneumoniae is the most common cause of community-acquired
pneumonia [1, 35–37]. Therefore, our findings may more accurately define the true burden of
pneumococcal disease in the US. Rates of pneumonia directly attributable to S. pneumoniae
range from 36.1 to 500 cases per 100,000 persons per year [4, 38].
Worldwide pneumococcal pneumonia mortality rates range considerably from 6% to
greater than 50% depending on disease severity and host factors, including age and
presence of comorbid conditions [39–43]. The non-invasive pneumococcal pneumonia 30day mortality rate we observed is similar to that previously reported in a Veteran population
(14.2% versus 12.8%) [44]. The pneumococcal bacteremia and meningitis mortality rates we
observed also agreed with previous findings, which range from 10% to greater than 40%
[45–49].
Overall, only a third of the patients in our study with serious infections had a history of
pneumococcal vaccination, which is much lower than the previously reported vaccination
rate of 85% for patients at VA facilities nationally in 2003 [50]. As we conducted our study in
older adults and observed significant increases in risk factors for S. pneumonia, it is likely
that a number of these non-vaccinated patients had indications for vaccination. This is
extremely concerning as non-vaccinated patients with indications for vaccination are more
likely to become infected with pneumococcus than those without indications, and nonvaccinated patients are also twice as likely to die if they develop invasive pneumococcal
disease [51, 52].
The sickest patients in our study were more likely to receive pneumococcal
vaccination. Therefore, the vaccinated patients likely had more healthcare exposures
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resulting in greater opportunities to receive a pneumococcal vaccination than the nonvaccinated patients. Increased pneumococcal vaccination awareness may be needed for
patients who are at risk of pneumococcal disease and have indications for vaccination but
have fewer healthcare exposures. The administration of vaccination in non-traditional
settings, such as pharmacies and shopping malls, may improve vaccine coverage in these
patients [53].
There are several limitations to this study. Our estimation of burden of non-invasive
pneumococcal disease may be an underestimate, particularly in the outpatient population, as
the value of cultures is limited in the diagnosis of many non-invasive pneumococcal
infections. For acute otitis media, the standard of diagnosis is with otoscopic examination not
bacterial cultures. For pneumonia, sputum samples are optional in most patients as utility is
limited by the inability of many patients to produce adequate sputum samples and by poor
specificity due to pneumococcal colonization of the upper airways [37]. For the inpatient
population, we attempted to increase the specificity of respiratory cultures by requiring a
diagnosis code for pneumonia. We did not include S. pneumoniae antigen detection tests to
define pneumococcal disease. Pneumococcal urinary antigen tests may be adequate to
diagnose pneumococcal pneumonia; however, sputum cultures are often still indicated at the
point of care for sensitivity testing to confirm the appropriate antimicrobial treatment [37].
Our vaccination rates may be lower than that previously reported as we defined
vaccination as documentation of pneumococcal vaccination administration in the previous 1,
5, and 10 years, while the earlier study considered vaccinated patients to be those with any
prior medical documentation indicating receipt of a vaccination [50]. Patients may have
received a pneumococcal vaccination outside the VA which would underestimate our
vaccination rates. However, our pneumococcal vaccination rates are comparable to the
national vaccination rate of 20.1% for high-risk adults aged 19 to 64 reported in the 2011
National Health Interview Survey [54].
Due to the retrospective nature of this study, isolates were not available and as such
serotype data was not available. Data on immunosuppressant use, such as corticosteroid
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and chemotherapy, was not available, which are risk factors for pneumococcal disease.
Additionally, there is always the potential for misclassification when relying on ICD-9 codes,
however, disease coding in the VA database has been validated for a number of conditions
and is determined to be of high quality [55–58]. Moreover, we identified pneumococcal
infections using microbiology data rather than ICD-9 codes. Finally, the generalizability of
our study is limited to the Veteran population.

CONCLUSION
We described the epidemiology of invasive and non-invasive pneumococcal disease in a
large, national population of older adults, who are at the greatest risk for pneumococcal
infections. We observed a concerning trend of increasing S. pneumoniae risk factors among
those with serious pneumococcal infections. With the aging population and the epidemic of
chronic illnesses, the burden of pneumococcal disease is likely to rise. Efforts to improve
vaccination rates among high-risk patients may be an important strategy to mitigate
increases in pneumococcal disease, however this requires further investigation.
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Table 1. Annual Incidence of Pneumococcal Disease by Healthcare and Age Group
Year
Totalc
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
Annualized percent change (%)
P value

5.8
6.0
5.9
6.0
6.0
5.9
5.6
4.9
4.0
2.9
-3.5
<0.001

Outpatient incidencea
50–64
≥65 years
years
2.4
3.4
2.5
3.4
2.5
3.4
2.7
3.3
2.7
3.3
2.7
3.2
2.6
3.0
2.2
2.7
1.8
2.2
1.3
1.6
-4.1
-3.1
0.001
0.003

Totalc
262.3
288.5
270.4
280.6
278.1
277.7
309.9
307.4
305.4
328.1
0.2
0.846

50–64
years
105.5
116.2
116.9
124.7
136.1
135.5
147.1
148.7
144.3
154.5
-0.6
0.391

Inpatient incidenceb
≥65 years
Serious
diseased
156.8
235.3
172.2
254.8
153.5
234.5
155.9
240.0
141.9
240.6
142.2
230.1
162.8
264.0
158.7
258.5
161.1
253.4
173.5
264.7
0.7
0.1
0.533
0.888

Invasive
diseasee
78.1
97.0
88.9
88.6
91.0
87.5
97.7
91.6
92.6
94.6
-1.0
0.454

Incidence based on all positive Streptococcus pneumoniae cultures from any site, unless otherwise indicated. aNumber of infections per
100,000 clinic visits. bNumber of infections per 100,000 hospital visits. cIncludes all patients aged ≥50 years. dIncludes only serious
pneumococcal infections (pneumonia, bacteremia, and meningitis). eIncludes only invasive pneumococcal disease (bacteremia, meningitis, and
bacteremic pneumonia).
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Table 2. Population Demographics, Comorbid Conditions, and Healthcare Exposures of Hospitalized Patients with Serious
Pneumococcal Infections by Infection Type
Variable

Totala
(n = 14,511)

Pneumoniab
(n = 9,193)

Age (years), mean (SD)
Male gender
White race
Region of facility
Midwest
Northeast
South
West
Treating specialty
General Medicine
Intensive care unit
Surgery
Other
Pneumococcal immunization
1 year prior to infection
5 years prior to infection
10 years prior to infection
History of multiple pneumococcal infectionse
Infection diagnosis previous year
Pneumoniaf
Bacteremiaf
Streptococcus species infectiong
Charlson comorbidity index, median (IQR)
Comorbid conditions
Heart failure
Chronic respiratory disease
Diabetes
Diabetes with complications

67.7 (10.6)
14,237 (98.1)
11,526 (79.4)

Bacteremia
(n = 3,735)

Meningitisc
(n = 44)

67.9 (10.3)
9,042 (98.4)
7,607 (82.7)

Bacteremic
pneumonia
(n = 1,529)
66.9 (10.5)
1,507 (98.6)
1,167 (76.3)

67.4 (11.2)
3,637 (97.4)
2,716 (72.7)

67.7 (10.6)
41 (93.2)
28 (63.6)

Invasive
diseased
(n = 5,318 )
67.2 (11.0)
5,195 (97.7)
3,919 (73.7)

3,430 (23.6)
2,206 (15.2)
5,414 (37.3)
3,461 (23.9)

2,297 (25.0)
1,510 (16.4)
3,107 (33.8)
2,279 (24.8)

326 (21.3)
238 (15.6)
633 (41.4)
332 (21.7)

798 (21.4)
455 (12.2)
1,639 (43.9)
843 (22.6)

7 (15.9)
<5
29 (65.9)
5 (11.4)

1,133 (21.3)
696 (13.1)
2,307 (43.4)
1,182 (22.2)

8,351 (57.5)
3,758 (25.9)
739 (5.1)
1,663 (11.5)

5,375 (58.5)
2,167 (23.6)
501 (5.4)
1,150 (12.5)

654 (42.8)
654 (42.8)
82 (5.4)
139 (9.1)

2,307 (61.8)
910 (24.4)
151 (4.0)
367 (9.8)

12 (27.3)
22 (50.0)
<5
6 (13.6)

2,976 (56.0)
1,591 (29.9)
238 (4.5)
238 (4.5)

1,274 (8.8)
4,386 (30.2)
5,274 (36.3)
5,279 (36.4)

831 (9.0)
2,855 (31.1)
3,441 (37.4)
3,277 (35.6)

120 (7.8)
435 (28.4)
513 (33.6)
566 (37.0)

318 (8.5)
1,084 (29.0)
1,305 (34.9)
1,421 (38.0)

<5
9 (20.5)
11 (25.0)
13 (29.5)

443 (8.3)
1,531 (28.8)
1,833 (34.5)
2,002 (37.6)

4,244 (29.2)
551 (3.8)
1,726 (11.9)
1 (0–3)

3,046 (33.1)
160 (1.7)
1,207 (13.1)
1 (0–2)

433 (28.3)
137 (9.0)
188 (12.3)
1 (0–3)

759 (20.3)
250 (6.7)
326 (8.7)
2 (0–3)

<5
<5
<5
0 (0–2)

1,198 (22.5)
391 (7.4)
519 (9.8)
2 (0–3)

2,118 (14.6)
5,827 (40.2)
2,344 (16.2)
328 (2.3)

1,269 (13.8)
4,034 (43.9)
1,287 (14)
192 (2.1)

250 (16.4)
559 (36.6)
243 (15.9)
24 (1.6)

595 (15.9)
1,233 (33)
806 (21.6)
112 (3)

<5
<5
6 (13.6)
-

849 (16.0)
1,793 (33.7)
1,057 (19.9)
136 (2.6)
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Tobacco Use
Alcohol Abuse
Mild liver disease
HIV/AIDS
Chronic renal disease
Dialysis
Transplant
Immunity disorders
Cancer
Metastatic cancer
Length of stay (days), median (IQR)
Inpatient mortality
30-day mortality

1,856 (12.8)
1,307 (9.0)
851 (5.9)
246 (1.7)
1,233 (8.5)
397 (2.7)
79 (0.5)
26 (0.2)
2,355 (16.2)
572 (3.9)
6 (3–13)
1,972 (13.6)
2,596 (17.9)

1,283 (14.0)
726 (7.9)
318 (3.5)
100 (1.1)
570 (6.2)
135 (1.5)
32 (0.3)
11 (0.1)
1,308 (14.2)
312 (3.4)
6 (3–12)
872 (9.5)
1,301 (14.2)

149 (9.7)
175 (11.4)
124 (8.1)
30 (2.0)
169 (11.1)
103 (6.7)
10 (0.7)
5 (0.3)
272 (17.8)
69 (4.5)
12 (6–25)
445 (29.1)
441 (28.8)

422 (11.3)
397 (10.6)
406 (10.9)
113 (3.0)
493 (13.2)
157 (4.2)
36 (1.0)
10 (0.3)
768 (20.6)
190 (5.1)
6 (4–12)
649 (17.4)
848 (22.7)

<5
7 (15.9)
<5
<5
<5
<5
7 (15.9)
<5
11 (6.5–15.5)
<5
5 (11.4)

573 (10.8)
581 (10.9)
533 (10.0)
146 (2.7)
663 (12.5)
262 (4.9)
47 (0.9)
15 (0.3)
1,047 (19.7)
260 (4.9)
7 (4–15)
1,100 (20.7)
1,295 (24.4)

Data are no. (%) of patients, unless otherwise indicated. aIncludes only serious pneumococcal infections (pneumonia, bacteremia, and
meningitis). bIncludes patients with positive pneumococcal respiratory cultures and corresponding pneumonia diagnosis. cIncludes patients with
positive pneumococcal cerebrospinal fluid cultures with or without positive pneumococcal blood cultures. dIncludes only invasive pneumococcal
disease (bacteremia, meningitis, and bacteremic pneumonia). eIncludes all infection types from any positive Streptococcus pneumoniae culture
site. fAttributed to any organism. gAny infection type attributed to any Streptococcus species. AIDS, acquired immunodeficiency syndrome; HIV,
human immunodeficiency virus; IQR, interquartile range; SD, standard deviation.
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Table 3. Annual Prevalence of Risk Factors for Streptococcus pneumoniae in Hospitalized Patients with Serious Pneumococcal
Infections
Year

Heart
failure
(%)

Chronic
respiratory
(%)

Diabetes
(%)

Liver
disease
(%)

HIV
(%)

2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
Annualized change in prevalence (%)
P value

11.1
14.4
12.2
14.0
14.1
13.4
13.9
16.2
16.7
18.6
0.6a
0.002

33.1
34.2
35.7
36.2
35.4
38.2
41.6
44.6
47.6
50.9
1.9a
<0.001

11.3
12.0
12.5
13.8
14.3
15.5
18.5
16.6
21.9
22.6
1.3a
<0.001

4.6
5.4
4.0
5.2
5.9
5.6
7.2
6.8
7.7
7.4
0.4a
<0.001

1.2
1.3
1.4
1.6
1.7
1.5
3.1
1.6
1.7
1.8
0.1
0.186

Renal
failure
or
dialysis
(%)
5.6
6.4
5.1
6.9
8.6
9.0
11.1
12.3
13.5
13.8
1.0a
<0.001

Immunity
disorder
(%)

Cancer
(%)

0.0
0.3
0.0
0.1
0.4
0.3
0.1
0.3
0.2
0.2
0.0
0.427

13.0
14.9
15.9
14.5
16.3
17.5
16.3
17.4
16.9
18.9
0.5a
<0.001
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Table 4. Population Demographics, Comorbid Conditions, and Healthcare Exposures
of Hospitalized Patients with Serious Pneumococcal Infections by Vaccination Status
Variable

Age (years), mean (SD)
Male gender
White Race
Region of Facility
Midwest
Northeast
South
West
Treating Specialty
General Medicine
Intensive care unit
Surgery
Other
History of multiple pneumococcal infectionsa
Infections previous year
Pneumoniab
Bacteremiab
Streptococcus species infectionc
Charlson comorbidity index, median (IQR)
Comorbid conditions
Heart failure
Chronic respiratory disease
Diabetes
Diabetes with Complications
Tobacco Use
Alcohol Abuse
Mild Liver Disease
Moderate or severe liver disease
HIV/AIDS
Chronic Renal Disease
Dialysis
Transplant
Immunity Disorders
Cancer
Metastatic Cancer
Length of stay (days), median (IQR)
Inpatient mortality
30-day mortality
Invasive Disease
Infection Type
Pneumonia
Bacteremic Pneumonia
Bacteremia
Meningitis

Notvaccinated
(n = 10,125)
67.7 (10.8)
9,921 (98.0)
7,951 (78.5)

Vaccinated
(n = 4,386)

P value

67.5 (10.1)
4,316 (98.4)
3,575 (81.5)

0.853
0.089
<0.001

2,473 (24.4)
1,519 (15.0)
3,583 (35.4)
2,550 (25.2)

957 (21.8)
687 (15.7)
1,831 (41.7)
911 (20.8)

<0.001

5,773 (57.0)
2,634 (26.0)
538 (5.3)
1,180 (11.7)
3,180 (31.4)

2,578 (58.8)
1,124 (25.6)
201 (4.6)
483 (11.0)
2,099 (47.9)

0.074

<0.001

2,694 (26.6)
350 (3.5)
1,156 (11.4)
1 (0-3)

1,550 (35.3)
201 (4.6)
570 (13.0)
1 (0-3)

<0.001
0.001
0.007
<0.001

1,438 (14.2)
3,845 (38.0)
1,574 (15.5)
223 (2.2)
1,256 (12.4)
917 (9.1)
576 (5.7)
127 (1.3)
144 (1.4)
823 (8.1)
269 (2.7)
55 (0.5)
11 (0.1)
1,584 (15.6)
403 (4.0)
6 (3-13)
1,414 (14.0)
1,836 (18.1)
3,787 (37.4)

680 (15.5)
1,982 (45.2)
770 (17.6)
105 (2.4)
600 (13.7)
390 (8.9)
275 (6.3)
69 (1.6)
102 (2.3)
410 (9.3)
128 (2.9)
24 (0.6)
15 (0.3)
771 (17.6)
169 (3.9)
6 (3-13)
558 (12.7)
760 (17.3)
1,531 (34.9)

0.041
<0.001
0.003
0.476
0.035
0.750
0.171
0.127
<0.001
0.016
0.375
0.750
0.002
0.004
0.718
0.768
0.045
0.245
0.004

6,338 (62.6)
1,094 (10.8)
2,651 (26.2)
35 (0.4)

2,855 (65.1)
435 (9.9)
1,084 (24.7)
9 (0.2)

0.049

Data are no. (%) of patients, unless otherwise indicated. Vaccination status based on receipt
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or not of a pneumococcal immunization in the five years prior to infection. aIncludes all
infection types from any positive Streptococcus pneumoniae culture site. bAttributed to any
organism. cAny infection type attributed to any Streptococcus species. AIDS, acquired
immunodeficiency syndrome; HIV, human immunodeficiency virus; IQR, interquartile range;
SD, standard deviation.
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